New White Paper: Characterization of Advanced Therapies – Leveraging Advanced Analytics to Avoid FDA Holds
Dana Cipriano, Senior Vice President of Testing and Analytical Services & Alexei Saveliev, Director of NGS Lab Operations
CBM experts Dana Cipriano, SVP of Testing and Analytical Services & Alexei Saveliev, Dir. of NGS Lab Operations, explore the latest strategies and technologies to develop a comprehensive, optimal approach to assay development and product characterization.
In this talk our experts cover on topics related to:
. CQA selection & assay development
. Orthogonal methods for product characterization
. Characterization of on-target gene editing efficiencies and risks of off-target effects
. Next-generation sequencing (NGS) for product characterization from discovery to clinic
In need of immediate assistance for your product development? Contact us here or simply call to speak with a CBM expert: 866-274-4009.